- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02947581
Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO) (SANTO)
A Randomized Trial of Combined Albendazole Plus Praziquantel for Subarachnoid Cysticercosis of the Sylvian Fissure or the Basal Cisterns
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Double-blind, randomized, placebo-controlled study in patients with subarachnoid cysticercosis of the basal cisterns or the Sylvian fissure, comparing in two parallel arms the efficacy of the standard of care anti-parasitic regime (30 days of ABZ at 15 mg/k/d, up to 1200 mg/k/d) with a combined regime using similar doses of ABZ and adding PZQ at 50 mg/k/d for the initial 15 days of anti-parasitic treatment. The study and interim analysis plan are designed to allow direct, concrete efficacy comparison in this deadly type of NCC while minimizing the risks of disease progression in the standard of care arm.
In short, this is a parallel group study with a dichotomous primary outcome variable. The main analysis will compare the proportions of patients obtaining the primary outcome at 6 months, using a Chi-square test in a bivariate analysis. A similar analysis will be used for the proportions of patients with a good clinical outcome, and the proportions of patients in whom lesion resolution sustains when assessed at month 12. A Student T test analysis will be used to compare for reduction in parasite volume and non-parametric Mann-Whitney test will be alternatively applied for non-normally distributed data. A non-parametric Spearman's Rho test will be used to assess the correlation between the proportions of cyst mass reduction with the decrease in antigen levels in each study group. A Chi-square test in a bivariate analysis will evaluate the association between negative antigen levels at 6 months versus the complete disappearance of cyst mass.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Lima, Peru, Lima 1
- Cysticercosis Unit, Instituto Nacional de Ciencias Neurologicas
-
Lima, Peru
- Hospital Nacional Cayetano Heredia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- - Male or female adult individuals (18 to 65 y.o.) with a diagnosis of basal subarachnoid cysticercosis (including locations in the Sylvian fissure or lower interhemispheric spaces) by neuroimaging and confirmed by serology.
- Baseline laboratory results along acceptable ranges (specifically defined in the study protocol).
- Willingness to accomplish the two-week minimum hospitalization required.
Exclusion Criteria:
- Previous therapy with ABZ or PZQ in the preceding 3 years (except for patients who received single-dose ABZ for intestinal parasites, or patients who received antiparasitic treatment between one and three years before enrollment but demonstrated lesion persistence or progression during the past 12 months).
- A type of NCC which can expose the patient to increased risk during the study, specifically: a) intraventricular cysts; b) cysts in brainstem; c) concomitant intraparenchymal lesions greater than 3 cm of diameter in addition to their SANCC lesions; d) more than 20 intraparenchymal cysts in addition to their SANCC lesions; or d) untreated ocular cysticercosis. Patients with a lateral ventricle cyst, less than 2 cm in diameter, without hydrocephalus or intracranial hypertension, can be included. The presence of concomitant intraparenchymal cysts of less than 3 cm in diameter will not exclude the patient unless there are more than 20 of them.
- Active pulmonary tuberculosis evidenced by positive chest X-ray and positive sputum smears, or symptoms compatible with tuberculosis (fever+sweats or fever+cough) not otherwise explained.
- Individuals with positive markers for active hepatitis.
- Systemic disease that may affect therapy or short-term prognosis, including but not limited to chronic renal failure, hepatic insufficiency, cardiac failure, and steroid-dependent immune diseases.
- Patients in unstable condition or with symptomatic intracranial hypertension (ICH). Definition of symptomatic ICH for this study is the presence of headaches, nausea, and vomiting, with papilledema at fundoscopic examination. Patients in this category can be considered for entrance into the study only after resolution of ICH by ventricular-peritoneal shunting or neuroendoscopic procedures involving CSF flow derivation. These procedures would be done as part of their standard medical care and are not part of the trial intervention.
- Pregnancy during anti-parasitic treatment. If a patient becomes pregnant after treatment, she will continue in the study but will have radiological exams delayed until after delivery.
- History of hypersensitivity to ABZ or PZQ
- Chronic or drug abuse as defined in the study protocol.
- Unwilling or unable to undergo MRI exams (like patients with ferromagnetic implants)
- Inability or unwillingness of subject or legal representative to give written informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interventions
Albendazole and praziquantel.
Albendazole: 15 mg/k/d up to 800 mg/d (days 1 to 20), followed by 15 mg/k/d up to 1200 mg/d (day 21 to 30) and prazicuantel (50 mg/k/d days 1 to 15).
|
Intervention - PZQ (50 mg/k/d, up to 3600 mg/d, for 15 days), as an add-on to ABZ treatment (15 mg/k/d, up to 800 mg/d for days 1-20, up to 1200 mg/d for days 21-30).
In order to maintain the double blind nature of the trial, ABZ placebo will be administered to individuals over 53 kg of weight until completing the equivalent doses in the comparison group.
Other Names:
|
Active Comparator: Comparison regime
Albendazole and praziquantel placebo.
Albendazole: 15 mg/k/d (days 1 to 30) and prazicuantel placebo in similar doses 50 mg/k/d (days 1 to 15).
|
PZQ placebo in similar doses, given during the initial 15 days of ABZ treatment at standard doses (15 mg/k/d up to 1200 mg/d for 30 days)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radiological efficacy at three months (3-month improvement).
Time Frame: Day 90 +/- 15 days
|
Thirty percent or greater decrease in the combined volume of all parasitic masses, evaluated by contrast-enhanced MRI 3 months after therapy onset, and recorded both as a dichotomous outcome and as a continuous quantification.
|
Day 90 +/- 15 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radiological efficacy at six months (marked improvement or "radiological cure") (evaluated only in patients with improvement at month 3).
Time Frame: Day 180 +/- 15 days
|
Total disappearance or greater than 50% decrease in the combined volume of subarachnoid parasites, evaluated by contrast-enhanced MRI 6 months after therapy onset, and recorded both as a dichotomous outcome and as a continuous quantification.
three.months
after treatment onset (comparative between treatment arms).
|
Day 180 +/- 15 days
|
Effect persistence at 12 months (no relapse) (evaluated only in patients with marked improvement at month 6) Effect persistence at 12 months (no relapse) (evaluated only in patients with marked improvement at month 6)
Time Frame: Day 365 +/- 15 days
|
No reappearance or re-growth of the parasitic lesions on contrast enhanced MRI at 12 months after therapy onset, recorded as a dichotomous outcome.
hypertension, or progressive neurologic deficits (in cognitive functions, motor function, gait, or other defined neurological signs) in a patient off steroid therapy, as assessed by a study neurologist 12 months post treatment.
|
Day 365 +/- 15 days
|
Clinically asymptomatic patient
Time Frame: 3, 6, and 12 months
|
No evidence of uncontrolled seizures, chronic severe headaches, intracranial hypertension, or progressive neurologic deficits (in cognitive functions, motor function, gait, or other defined neurological signs) in a patient off steroid therapy, as assessed by a study neurologist at 3, 6, and 12 months post treatment.
|
3, 6, and 12 months
|
Decrease in serum levels
Time Frame: 3 months
|
will be measured at 3 months, and expressed as a proportion of the baseline level.
This variable will be compared between arms
|
3 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hector H. Garcia Lescano, Ph.D, Universidad Peruana Cayetano Heredia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Infections
- Central Nervous System Infections
- Parasitic Diseases
- Helminthiasis
- Cestode Infections
- Central Nervous System Helminthiasis
- Central Nervous System Parasitic Infections
- Cysticercosis
- Taeniasis
- Neurocysticercosis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antiprotozoal Agents
- Antiparasitic Agents
- Anthelmintics
- Antiplatyhelmintic Agents
- Anticestodal Agents
- Albendazole
- Praziquantel
Other Study ID Numbers
- 61449
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Informed Consent Form (ICF)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurocysticercosis
-
Oregon Health and Science UniversityNational Institute of Neurological Disorders and Stroke (NINDS); Universidad...WithdrawnSubarachnoid Neurocysticercosis
-
Technical University of MunichCompletedNeurocysticercosis | TaeniosisZambia
-
National Institute of Mental Health (NIMH)CompletedHealthy | NeurocysticercosisUnited States
-
Technical University of MunichNational Institute for Medical Research, Tanzania; University of Zambia; Sokoine...CompletedNeurocysticercosisTanzania
-
Johns Hopkins Bloomberg School of Public HealthUniversidad Peruana Cayetano Heredia; School of Veterinary Medicine, Universidad...WithdrawnTenia Solium Infection
-
Universidad Peruana Cayetano HerediaNational Institute of Neurological Disorders and Stroke (NINDS)CompletedEpilepsy | NeurocysticercosisPeru
-
Dario ScaramuzziUniversity Ghent; National Institute for Medical Research, Tanzania; University... and other collaboratorsNot yet recruiting
-
University of ZambiaCompleted
-
National Institute of Mental Health (NIMH)CompletedHealthy | NeurocysticercosisUnited States
-
Universidad Peruana Cayetano HerediaTerminated
Clinical Trials on Albendazole and praziquantel
-
DBL -Institute for Health Research and DevelopmentCompleted
-
Navrongo Health Research Centre, GhanaDBL -Institute for Health Research and DevelopmentUnknownAnemia | Malaria | Helminthiasis | Schistosomiasis | Change in Sustained AttentionGhana
-
DBL -Institute for Health Research and DevelopmentCompletedMalaria | Anaemia | HepatosplenomegalyTanzania
-
Catholic University of Health and Allied SciencesUniversity of Cambridge; National Institute for Medical Research, TanzaniaUnknownHematologic Diseases | Anemia | Opportunistic Infections | Human Immunodeficiency Virus I Infection | Intestinal Helminthiasis | Intestinal SchistosomiasisTanzania
-
Swiss Tropical & Public Health InstituteMerck KGaA, Darmstadt, Germany; University Hospital Inselspital, Berne; Ifakara...TerminatedHIV Infections | HelminthiasisTanzania
-
DBL -Institute for Health Research and DevelopmentCompleted
-
Dario ScaramuzziUniversity Ghent; National Institute for Medical Research, Tanzania; University... and other collaboratorsNot yet recruiting
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Leiden University Medical CenterSwiss Tropical & Public Health Institute; Centre Suisse de Recherches Scientifiques...CompletedSchistosomiasisCôte D'Ivoire
-
Universidad Peruana Cayetano HerediaNational Institute of Neurological Disorders and Stroke (NINDS)CompletedEpilepsy | NeurocysticercosisPeru